Molecular Health appoints Christian Meisel, MD, PhD, as Chief Medical Officer

Newsroom

All news

Molecular Health appoints Christian Meisel, MD, PhD, as Chief Medical Officer

Heidelberg, Germany – Tuesday, May 7, 2019–Molecular Health, a leading company in the field of data science for precision medicine and specializing in the development of products and services leveraging its proprietary biomedicine technology platform Dataome, today announced the appointment ofDr. Christian Meisel as corporate Chief Medical Officer (CMO).

 

Dr. Meiselcomes to Molecular Health with over 25years of experience in the healthcare sector–including clinical practiceand research &development across academia and the biopharmaceutical industry–andmore than 10 years in senior pharma leadership roles. As anMDandPhD with additional qualifications in computer science and extensive experience in precision medicine, Dr. Meisel will be responsible for all clinical aspectsof Molecular Health’sportfolioand development. As a member of the company’s leadership,he will also provide strategicdirection and leadership in the development of Molecular Health.

 

Dr. Friedrich von Bohlen, Co-founder and CEO of Molecular Health, said:”Weare very pleasedto have Dr. Meisel join as our Chief Medical Officer. He not only is anexperiencedphysician but, next to his background in computer science, also brings an extensivetrack record and expertise in precision medicineacross the biopharmaceutical and diagnostics industry. With his broadexperience in molecular diagnostics and drug development,he is a perfect addition to our development and commercial teams and willstrategically enhanceand further sharpen thefocus of our offerings to pharma, physicians, providers, payersand the financial industry. The CMO position is key for our growth strategy, and we are happy to havefound Christianfor this important role at Molecular Health.”

 

Dr. Meisel adds: “I am very much looking forwardto joiningMolecular Health –a company at the forefront of the digital transformation of medicine and R&D –as a member of the executive team. I will bring my first-hand experience and deep knowledge of the demandsof patients and healthcare providers to further improveMolecular Health’s innovative solutions to impact patient care,therapeutic and diagnostic product development,and meet the growing needs of the medical community in the digitalization of healthcare.”

 

Dr. Christian Meisel joins Molecular Health from Roche where heserved for more than 14 years in numerous senior leadership roles, including Global Head Personalized Healthcare Platform, acting Global Head Translational Medicine Oncology, and Global Head Biomarkers and Translational R&D Innovation. Dr. Meisel is board-certified in Internal Medicine and in Clinical Pharmacology, holds an MD from the Technical University of Munich, and a PhD from Charité Berlin, where he also served as associate professor and leader of a bioinformatics research group.

 

About Molecular Health

Molecular Health is a data science-focused artificial intelligencecomputing company enabling and improving decision making in precision medicine for healthcare organizations.The company offerings are based on the capture, curation, integration, and analysis of large biomedical and drug data sets andcombining them with novel artificial intelligence and machine learning (AI/ML) technologies.For more than a decade, the company has been developingDataome, a unique high-quality curated, interoperable system that combines clinico-molecular and drug data with proprietary analytical processes.Dataome –stand alone or in combination with customer data –enables the unlocking of actionable intelligence at the molecular level toa)improve diagnosis and therapy decisions by physicians and patients;b) enrich and support better drug discovery, drug development, trial optimization, drug differentiation and positioning for pharma and healthcare organizations;andc) more accurately predict the likelihood of success and likelihood of approval of drug candidates in clinical development for better trial prioritization and resource and investment allocation.For more information,visit www.molecularhealth.com.

 

Molecular Health GmbH
Thomas König
Head of Marketing
thomas.koenig@molecularhealth.com

 

Media Relations
MC Services AG
Katja Arnold, Eva Bauer, Laurie Doyle
molecularhealth@mc-services.eu
+49-89-210 2280

Molecular Health ’s MH Guide shortlisted for the German Digital Health Award 2019

Newsroom

All news

Molecular Health ’s MH Guide shortlisted for the German Digital Health Award 2019

• Molecular Health Guide (MH Guide) shortlisted forthe German Digital Health Award 2019
• Novartis and Sandoz/Hexal nominate seven out of 119 submissions
• MH Guide enables evidence-based cancer therapy decisions for physicians, patients and health insurers

 

Heidelberg, Germany–Monday, February 18, 2019–Molecular Health (MH), a leading company in the field of data science for precision medicine and specializing in the development of products and
services leveraging its proprietary biomedicine technology platform Dataome, has been shortlisted for the German Digital Health Award 2019. As Novartis Pharma and Sandoz Germany/Hexal announced earlier, MH Guide is one of only seven entriesselected from a total of 119 submissions. The German Digital Health Award is given to sustainable digital solutions to improve healthcare in Germany. The
2nd annual awards ceremony will take place in Berlin on March 20, 2019.

 

Dr. Friedrich von Bohlen, Co-founder and CEO of Molecular Health, said: ”We are delighted to be shortlisted for the German Digital Health Award 2019 and by the recognition this means for our work. At Molecular Health, we are constantly seeking smart solutions to address the challenges in cancer healthcare. Nine renowned experts have been appointed to the jury by Novartis, and their
nomination reinforces that we are following a future-oriented and sound path.”

 

With MH Guide, physicians in their everyday cancer practice can make an evidence-based therapy decision that takes into account the individual patient’s tumor characteristics. Utilizing MH’s
proprietary technology platform Dataome, MH Guide generates a summary of potentially effective medications, potentially ineffective medications, and medications that may pose a higher risk of adverse reactions or be predictive for an increased risk of cancer progression. MH Guide is the first software product approved as an IVD medical device by the EU and is currently eligible for reimbursement.

 

About Molecular Health
Molecular Health is a data science-focused artificial intelligence computing company enabling and improving decision making in precision medicine for healthcare organizations.The company offerings are based on the capture, curation, integration, and analysis of large biomedical and drug data sets and combining them with novel artificial intelligence and machine learning (AI/ML) technologies. For more than a decade, the company has been developing Dataome, a unique high-quality curated, interoperable system that combines clinico-molecular and drug data with proprietary analytical processes.Dataome – stand alone or in combination with customer data – enables the unlocking of actionable intelligence at the molecular level to a) improve diagnosis and therapy decisions by physicians and patients; b) enrich and support better drug discovery, drug development, trial optimization, drug differentiation and positioning for pharma and healthcare organizations; and c) more accurately predict the likelihood of success and likelihood of approval of drug candidates in clinical development for better trial prioritization and resource and investment allocation.
For more information,visit www.molecularhealth.com.

 

Related News:
https://www.novartis.de/news/media-releases/shortlist-mit-sieben-projekten-fuer-den-digitalen-gesundheitspreis-von-novartis
https://www.novartis.de/aktuelles/digitaler-gesundheitspreis

 

Molecular Health GmbH
Thomas König
Head of Marketing
thomas.koenig@molecularhealth.com

 

Media Relations
MC Services AG
Katja Arnold, Eva Bauer, Laurie Doyle
molecularhealth@mc-services.eu
+49-89-210 2280

Molecular Health Licenses its Proprietary Predictive Analytics to DATEN CAPITAL

Newsroom

All news

Molecular Health Licenses its Proprietary Predictive Analytics to DATEN CAPITAL

• Molecular Health Predict enables highly accurate estimates of clinical trial success probabilities 
• Exclusive license for the financial industry granted to DATEN CAPITAL  
• Molecular Health to receive an annual license fee and success-based payments  

 

Heidelberg, Germany and Boston, MA — Monday, January 7, 2019 — Molecular Health, a leading company in the field of data science for precision medicine and specializing in the development of products and services leveraging its proprietary biomedicine technology platform Dataome®, is pleased to announce that it has granted an exclusive license for Molecular Health Predict (MH Predict) to DATEN CAPITAL LLP (DATEN), for its use in the financial industry. MH Predict was developed by Molecular Health to calculate the likelihood of success of drug clinical trials, and DATEN is a private limited liability partnership founded to commercialize data-science, AI-driven approaches to investing. Molecular Health will receive an annual license fee as well as success-based payments from DATEN. Friedrich von Bohlen, PhD, Cofounder & CEO of Molecular Health GmbH, said: “We are very excited to announce this exclusive license for the financial industry with DATEN CAPITAL. Understanding and effectively predicting the likelihood of success of clinical trials is critical to achieving better efficiencies and savings in drug R&D – which today still represents billions of dollars of annual losses due to trial attrition for both pharmaceutical companies and investors. We believe that MH Predict will drive a true paradigm shift in drug development, resource and investment allocations and ultimately patient outcomes. We look forward to launching this product also to the pharmaceutical industry in early 2019.” “I came to know Friedrich von Bohlen and Molecular Health during my time in investment banking at Goldman Sachs. After learning more about the company, and assessing its technology, I became increasingly convinced of the potential for Molecular Health to transform the drug development industry. Our mission when founding DATEN CAPITAL was to build a data-science, AI-driven approach to allocating capital. This is why we are particularly excited to have obtained an exclusive license to apply MH Predict to the financial markets. Our aim, and our belief, is that we will help enable the biopharmaceutical industry to deliver new drugs to the market in a much better, faster and cheaper way,” said Amit R. Karna, CFA, Managing Partner at DATEN CAPITAL LLP.  

 

About MH Predict  

MH Predict is an artificial intelligence (AI) based product that predicts the likelihood of success of a clinical trial to achieve its endpoints. Models are designed and validated based on a range of public and proprietary data sources, including Dataome®, a proprietary database custom built by Molecular Health over 10 years and with over €150m of invested capital.  

 

About Molecular Health  

Molecular Health is a data science-focused artificial intelligence computing company enabling and improving decision making in precision medicine for healthcare organizations. The company offerings are based on the capture, curation, integration, and analysis of large biomedical and drug data sets and combining them with novel artificial intelligence and machine learning (AI/ML) technologies. For more than a decade, the company has been developing Dataome®, a unique high-quality curated, interoperable system that combines clinico-molecular and drug data with proprietary analytical processes. Dataome® – stand alone or in combination with customer data – enables the unlocking of actionable intelligence at the molecular level to a) improve diagnosis and therapy decisions by physicians and patients; b) enrich and support better drug discovery, drug development, trial optimization, drug differentiation and positioning for pharma and healthcare organizations; and c) more accurately predict the likelihood of success and likelihood of approval of drug candidates in clinical development for better trial prioritization and resource and investment allocation. For more information, visit www.molecularhealth.com.  

 

About DATEN CAPITAL

DATEN CAPITAL LLP (DATEN) is a private limited liability partnership incorporated in England and Wales (registered no: OC424550). The firm was founded in 2018 with a mission to apply data-science, AI-driven solutions to the financial markets. DATEN plans to initially focus on the biotech sector, primarily in the US and Europe. The Managing Partner for DATEN is Amit R. Karna, CFA, a former investment banker who spent ten years in the healthcare team at Goldman, Sachs & Co., based initially in New York before transferring to London. DATEN CAPITAL LLP is backed by leading investors and individuals in the healthcare and technology sectors. For more information, visit www.datencapital.com

 

Molecular Health Predict (MH Predict)
Blanca Baez
Global Head of Pharma & Biotech
 
Molecular Health GmbH
Thomas König
Head of Marketing
 
Media Relations
MC Services AG
Katja Arnold, Eva Bauer, Laurie Doyle
+49 – 89 – 210 2280
 

MH Guide for labs: Augment your annotations quickly

Newsroom

All news

MH Guide for labs: Augment your annotations quickly

Benefit from our software-aided interpretations for personalized cancer treatment

• Latest and comprehensive clinical evidence gathered from top publications/databases
• Oncologist/pathologist reviewed annotations that include treatment options
• Seamless integration into existing lab workflow
• Intuitive UI/UX
• Cloud-based portal for rapid and secure processing

Molecular Health to attend key conferences in 3rd quarter 2018

Newsroom

All news

Molecular Health to attend key conferences in 3rd quarter 2018

Heidelberg, Germany and Boston, USA – July 3, 2018 – Molecular Health (MH), a leading biomedical company that is transforming molecular data into clinically actionable information for efficient and safer
cancer treatment options based on its proprietary Dataome® technology platform, announced that the company is going to attend several industry and scientific conferences in the third quarter 2018.

July 

The 16th Annual Meeting of Japanese Society of Medical Oncology JSMO, July 19 – 21, 2018 – Kobe International Conference Center, Japan. Attendance: 3 posters and 1 oral presentation 
– MH BRCA – Confident BRCA1/2 variant classification: using ACMG and public data for systematic molecular profiling
– Intelligent treatment decision support combining variant interpretation and phenotype analytics can transform healthcare
– Comprehensive treatment decision support of more than 1,000 patients by the medical device Molecular Health Guide®
– Evidence-based software for NGS in pancreatic cancer: first results from the PePaCaKa study   

August 

The 9th Annual Cancer Genomics Consortium CGC Meeting, August 6 – 8, 2018 – Nashville, TN, USA. Attendance: Molecular Health booth.   

September 

Molekularpathologie-Symposium, September 5-9, Gera, Germany. Attendance: lecture from Dr. Stephan Brock CTO of Molecular Health.  
Heidelberger Myelomtage, September 21 – 23, 2018 – Im Neuenheimer Feld 410, 69120 Heidelberg, Germany. Attendance: Molecular Health booth.  
ISPOR Asia Pacific 2018, September 8 – 11, 2018 – Kei Plaza Hotel, Tokyo, Japan. Attendance: Poster presentation. 
– MH EFFECT® – A novel technology for the molecular analyses of Real-world outcomes/adverse event data. 

Molecular Health launches MH Mendel for the genetic diagnosis of hereditary diseases

Newsroom

All news

Molecular Health launches MH Mendel for the genetic diagnosis of hereditary diseases

• MH Mendel combines the most relevant information for the diagnosis of hereditary diseases  
• MH Mendel helps patients and supports physicians through most modern and comprehensive precision medicine technologies and expertise 
• MH Mendel becomes an integral part of IVD registered Molecular Health Guide® 3.0

 

Heidelberg, Germany and Boston, USA – June 11, 2018 – Molecular Health (MH), a leading biomedical company that is transforming molecular data into clinically actionable information for efficient and safer cancer treatment options based on its proprietary Dataome® technology platform, has introduced Molecular Health Guide® Mendel (MH Mendel) as part of the established Molecular Health Guide® (MH Guide), a comprehensive software solution for precision medicine. MH Mendel, an integral part of the MH Guide 3.0, a registered IVD product, supports human geneticists in creating a diagnostic report based on their own variant classifications. MH Mendel combines the information that is most relevant for the diagnosis of hereditary diseases. Data from a variety of sources are provided to help human geneticists to assess and classify variants detected in their patients. MH Mendel includes population frequencies, reported clinical significance, and functional impact predictions for a plethora of variants. For analysis of germline variants associated with hereditary diseases, MH Mendel supports human geneticists in managing their own variant classifications and interpretations as well as in creating diagnostic reports. ”Genetic tests can reveal a predisposition to rare hereditary diseases. Today some hereditary diseases can be managed. Early detection and precise understanding is important to initiate treatment and to prevent avoidable irreparable defects. Results of genetic tests analyzed and evaluated by MH Mendel can reveal ae predisposition to diseases and help physicians to find the exact molecular cause and to create a personalized diagnostic report for each patient “, says Dr. Stephan Brock, CTO of Molecular Health. “We are glad that with MH Mendel we can now help patients and support physicians with our advanced and highly curated and integrated precision medicine technologies and expertise.” 

Molecular Health launches Molecular Health Guide 3.0, providing improved support for precision medicine

Newsroom

All news

Molecular Health launches Molecular Health Guide 3.0, providing improved support for precision medicine

New features for intuitive biomarker classification and improved usability 

Heidelberg, Germany and Boston, USA – June 1, 2018 – Molecular Health (MH), a leading company in the field of precision medicine, specialized in the development of products and services leveraging their proprietary Dataome® technology platform, has launched Version 3.0 of Molecular Health Guide® (MH Guide), a comprehensive software solution for precision medicine. MH Guide compares patient-specific molecular information with biomedical knowledge to deliver an interactive, editable, medical report that supports treating physicians in evaluating the range of therapy options identified for the unique genomic profile of the patient. MH Guide is registered as an in vitro diagnostic device in the EU.

 

Physicians need to understand and interpret numerous biomarkers to assess their significance and make a reliable statement on the suitability of a specific cancer therapy. MH Guide identifies clinically significant variants from panel or whole exome analyses and provides physician-approved variant interpretations describing their clinical significance in the context of the patient’s disease. Physicians use this expert-curated knowledge on each variant and follow clickable references to the peer-reviewed sources as a basis for their clinical reports.

 

Version 3.0 comes with an improved AMP guideline-compliant biomarker classification scheme and supports HGVS variant nomenclature.  MH Guide 3.0 users can now incorporate results from other important diagnostic tests in their reports, such as protein expression, mutational burden, and microsatellite instability. Customizable gene filters mean physicians can streamline the workflow to focus on standard panels for genes of interest. Variant details from standard sources recommended by variant classification guidelines are now shown in MH Guide, in addition to the physician-approved variant interpretations, to support the physician in assessing the clinical significance of a variant. The MH Order portal provides order management tools for seamless communication between labs, hospitals, and Molecular Health.

 

“MH Guide 3.0 marks a further milestone in cancer treatment based on the genetic variants in a tumor. It gives the treating oncologist a fast and comprehensive overview of treatment recommendations,” said Dr. Rudolf Caspary, CIO of Molecular Health. “We can help to significantly facilitate and improve the daily clinical routine of the treating physicians, while delivering well-informed therapy decisions. Ultimately, this benefits patients – and the entire healthcare system.”

 

Prof. Dr. Matthias Löhr, Professor of Gastroenterology at the Karolinska Institutet in Stockholm, commented “As longstanding users of MH Guide we are especially impressed by the quality of the results and their clear presentation in version 3.0 of MH Guide. This makes MH Guide easy to use and easy to integrate in our daily routine. We can focus on the essentials – making informed decisions on the best therapy available and the best care for each individual patient.” 

 

About Molecular Health
Molecular Health(MH)is a computational biomedicine company focused on the capture, curation, integration, and analysis of large data sets in the field of biomedicine and medical products and combining them with novel artificial intelligence and machine learning (AI/ML) technologies to enable precision medicine. Overmore than a decade, the company has developed Dataome®, a unique, high-quality curated, interoperable system that combines clinico-molecular drug data and analytical processes. Dataome, in combination with novel AI/ML technologies, creates a totally new approach for prognostic and predictive in silico science that can guide some of the most promising yet most challenging domains of precision medicine.

 

For more information,

visit www.molecularhealth.com

Carla Mertens
Molecular Health GmbH
Carla.mertens@molecularhealth.com
HGVS, Human Genome Variation Society; AMP, Association for Molecular Pathology

Molecular Health receives grant from Bill & Melinda Gates Foundation

Newsroom

All news

Molecular Health receives grant from Bill & Melinda Gates Foundation

Molecular Health to pursue drug repurposing in tuberculosis treatment and perinatal complications 

 

Molecular Health receives grant from Bill & Melinda Gates Foundation 

Heidelberg, Germany/Boston, MA, May 16, 2018. Molecular Health announces it was awarded a grant from the Bill & Melinda Gates Foundation. Through the program enabled by the grant, Molecular Health (MH) will leverage computational biomedicine technology and domain expertise captured in MH core assets, Dataome® knowledgebase and MH Effect™ software, to help find shorter, more effective and better-tolerated treatment regimens for TB, and to explore ways to address perinatal complications in developing countries. Dataome® is MH’s biomedicine knowledgebase with comprehensive, current and curated clinico-molecular data and information on targets, molecules, diseases, variants, pathways, drugs and outcomes and will be utilized to identify treatment improvement opportunities in these two areas of unmet need, deriving novel insights on drug outcomes from other areas, such as immuno-oncology. MH Effect™ will allow MH experts to tap onto millions of patient records on drug outcomes to efficiently draw and test treatment hypotheses. Blanca Baez, Global Head of Pharma & Biotech at Molecular Health, expressed: “Our value proposition to drug discovery and drug development is to employ highly specialized in silico research and machine learning techniques to speedily generate, prove and disprove hypotheses for novel, repurposed or combined drug treatments to improve efficacy and safety in specific patient profiles. We do this through clinico-molecular analytics on drug target, mode of action and disease pathways. This grant allows us to continue delivering on this promise.” 

Molecular Health to pursue drug repurposing in tuberculosis treatment and perinatal complications

Newsroom

All news

Molecular Health to pursue drug repurposing in tuberculosis treatment and perinatal complications

Molecular Health receives grant from Bill & Melinda Gates Foundation

Heidelberg, Germany/Boston, MA, May 16, 2018. Molecular Health announces it was awarded a grant from the Bill & Melinda Gates Foundation. Through the program enabled by the grant, Molecular Health (MH)will leverage computational biomedicine technology and domain expertise captured in MH core assets, Dataome® knowledgebase and MH Effect™ software, to help find shorter, more effective and better‐tolerated treatment regimens for TB, and to explore ways to address perinatal complications in developing countries.

 

Dataome® is MH’s biomedicine knowledgebase with comprehensive, current and curated clinico-molecular data and information on targets, molecules, diseases, variants, pathways, drugs and outcomes and will be utilized to identify treatment improvement opportunities in these two areas of unmet need, deriving novel insights on drug outcomes from other areas, such as immuno-oncology. MH Effect™ will allow MH experts to tap onto millions of patient records on drug outcomes to efficiently draw and test treatment hypotheses.

 

Blanca Baez, Global Head of Pharma & Biotech at Molecular Health, expressed: “Our value proposition to drug discovery and drug development is to employ highly specialized in silico research and machine learning techniques to speedily generate, prove and disprove hypotheses for novel, repurposed or combined drug treatments to improve efficacy and safety in specific patient profiles. We do this through clinico-molecular analytics on drug target, mode of action and disease pathways. This grant allows us to continue delivering on this promise.”

 

About Molecular Health
Molecular Health, a computational biomedicine company, is focused on capturing, curating, integrating, and analyzing biomedical data and knowledge to enable precision medicine. For over a decade, the company has built and developed Dataome®, a unique highly-curated and interconnected reference system that includes clinical, molecular and drug data. Dataome® enables integration and referencing of further drug outcomes data, including electronic medical records and clinical trial data. These are used to run clinico-molecular analyses to elucidate and predict outcomes in specific patient profiles and
inform the discovery and development of more effective and safer therapies. MH Effect™ is one of the software applications MH has packaged to enable advanced clinico-molecular analytics on drug outcomes. Most recently, Dataome® enabled the development of a new AI algorithm that predicts likelihood of success and approval of clinical trials and drug development programs, MH Predictive Engine.

 

https://www.molecularhealth.com

Contact Molecular Health

Blanca Baez
Global Head of Business Development – Pharma & Biotech
blanca.baez@molecularhealth.com

SAP is expanding the COPE® program and now also covers the cost of tumor analysis for employees affected by cancer in Australia

Newsroom

All news

SAP is expanding the COPE® program and now also covers the cost of tumor analysis for employees affected by cancer in Australia

Heidelberg, Walldorf, 6 April 2018. From 26 March 2018, SAP will provide access to the “Corporate Oncology Program for Employees” (COPE®), developed by Molecular Health and offered by the Institute of Immunology and Genetics (IIG), also in Australia: If cancer is diagnosed in a SAP employee, the COPE program enables the affected person to have a molecular genetic analysis of the tumor genome prepared in order to find indications for promising therapies. 

 

Approximately 45% of men and 35% of women receive a cancer diagnosis during their lifetimes. Thanks to new technologies for molecular genetic analysis and clinical interpretation, however, cancer patients can now be treated more effectively than ever before. COPE is a milestone in advancing precision medicine. It illustrates SAP’s innovation mindset and caring culture, and the role that SAP HANA® can play in improving decision-making for patient treatment. In the spirit of SAP’s purpose to improve people’s lives, we are dedicated to investing in the health and wellbeing of our employees and to providing innovative benefit options that support colleagues through challenging times. 

 

With COPE, SAP offers eligible employees free and confidential access to precision medicine through an in-depth molecular-medical analysis aimed at helping doctors make better-informed treatment decisions. “Although COPE is not an actual therapy, the program provides treating doctors with information to make better-informed treatment decisions. A doctor treating oncologist receives this recommendation, which incorporates the patient’s genetic profile at the exact moment a decision has to be made. Therefore, treating oncologists can rely, that every recommendation is based on the latest, state-of-the-art science and technology. We believe that the program offers considerable added value for our affected colleagues”, says Dr. Natalie Lotzmann, Global Vice President HR, Head of Global Health Management, SAP. “Employees are the biggest asset of a company. We are delighted that SAP now also in Australia will help their employees affected by cancer through our COPE program”, says Friedrich von Bohlen, CEO of Molecular Health. 

 

Within the context of COPE, Molecular Health Guide™ (MH Guide) is being used: The software processes the genetic sequencing data in a very short time and analyses changes in the tumour genome of the patient. MH Guide matches this individual genetic information with biomedical knowledge currently available worldwide. On the basis of the most recent knowledge, this enables the treating doctors to identify a therapy with the highest potential for the tumour profile and to reduce potential side effects as much as possible. MH Guide thus supports the doctor in the efficient preparation of a therapy recommendation tailored to the individual patient, but the therapy decision is still the responsibility of the treating doctor. Confidentiality is a natural component of this process. The patient remains anonymous. Patient-related information remains confidential and will not be disclosed to third parties or the employer. COPE is offered by several global companies to provide employees free access to a molecular tumour analysis. 

www.cope-iig.com